Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.

  title={Treatment options available for bacillus Calmette-Gu{\'e}rin failure in non-muscle-invasive bladder cancer.},
  author={David R A Yates and Maurizio A. Brausi and James W. Catto and Guido Dalbagni and Morgan Roupr{\^e}t and Shahrokh F Shariat and Richard Joel Sylvester and Johannes Alfred Witjes and Alexandre R. Zlotta and Juan Palou-Redorta},
  journal={European urology},
  volume={62 6},
CONTEXT Intravesical bacillus Calmette-Guérin (BCG) is a standard conservative treatment for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). Many patients will experience recurrence or progression following BCG and are termed BCG failures. OBJECTIVE To summarise the current treatment options available for patients with high-risk NMIBC who experience BCG failure. EVIDENCE ACQUISITION We searched the Medline, Embase, and Cochrane Trials databases for studies of BCG failure… CONTINUE READING